Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 7, 2024
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
Strong cumulative prescriber growth, 45% year-over-year increase
52% year-over-year prescription fill increase; 39% increase since Q1 2024
NASDAQ:EVOK (6/11/2025, 8:00:02 PM)
3
+0.15 (+5.26%)
Find more stocks in the Stock Screener
